- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02435628
Relationship Between Psychosocial Factors, Health Literacy, Quality of Life and Satisfaction With Medical Visits in Adults With NF
Relationship Between Psychosocial Factors, Health Literacy, Quality of Life and Satisfaction With Medical Visits in Adults With Neurofibromatosis 1, Neurofibromatosis 2, and Schwannomatosis
Study Overview
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age 18 or older
- Can read and speak English at or above the 6th grade level
- Diagnosis of neurofibromatosis type 1, neurofibromatosis type 2, or schwannomatosis
Exclusion Criteria:
- Severe active or untreated major mental illness that would interfere with study participation, to be determined at the discretion of the study investigator (e.g. untreated psychosis or suicidality)
- Unable or unwilling to participate
- Unable or unwilling to complete psychological assessments online via the REDCap or Assessment Center systems.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Satisfaction Questionnaires
After enrollment, subjects will be given baseline measures to assess demographics, psychosocial factors, and health literacy. This assessment will occur online via Computerized Assessment Center. Participants will complete the PROMIS battery of measures assessing: depression, anxiety, anger, fatigue, pain behavior and interference, physical function, satisfaction with discretionary social activities, satisfaction with social roles, and health literacy. Participants will also complete the FFFHL scale. Upon completion of the baseline assessments, the participant will meet with their doctor at the NF clinic for a routine appointment. Post-treatment assessments will be administered immediately after completion of the medical visit. This assessment will evaluate the participant's satisfaction with the appointment in the NF clinic using the MISS and CAHPS surveys. This will be done online via REDCap. |
All subjects will complete baseline psychological assessments prior to their medical visit.
Upon completion of their routine medical visit, subjects will complete a post-test assessment measuring their satisfaction with the visit.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient Reported Outcomes Measurement Information System (PROMIS)
Time Frame: Baseline (pre-medical visit)
|
A battery of measures assessing: depression, anxiety, anger, fatigue, pain behavior and interference, physical function, satisfaction with discretionary social activities, satisfaction with social roles, and health literacy.
|
Baseline (pre-medical visit)
|
|
Functional, Communicative and Critical Health Literacy (FFFHL) scale
Time Frame: Baseline (pre-medical visit)
|
Measures one's health literacy, the capacity of individuals to access, understand, and use health information to make informed and appropriate health-related decisions.
|
Baseline (pre-medical visit)
|
|
Medical Interview Satisfaction Scale (MISS)
Time Frame: Participants will be followed for the duration of their medical visit, an expected average of no more than 2 hours.
|
Measures patient satisfaction with individual doctor-patient consultations.
|
Participants will be followed for the duration of their medical visit, an expected average of no more than 2 hours.
|
|
Consumer Assessment of Healthcare Providers and Systems (CAHPS) survey
Time Frame: Participants will be followed for the duration of their medical visit, an expected average of no more than 2 hours.
|
Asks patients to report on and evaluate their experiences with health care.
This survey covers topics that are important to consumers and focus on aspects of quality that consumers are best qualified to assess, such as the communication skills of providers and ease of access to health care services.
|
Participants will be followed for the duration of their medical visit, an expected average of no more than 2 hours.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Age, Gender, Ethnicity, and Race of Patients with NF
Time Frame: Baseline (pre-medical visit)
|
The questionnaire asks for the patient's age, gender, ethnicity, and race as part of the basic demographics.
|
Baseline (pre-medical visit)
|
|
Visual Analog Health Scale
Time Frame: Participants will be followed for the duration of their medical visit, an expected average of no more than 2 hours.
|
Measures one's current health on a scale from 0 ("very poor") to 10 ("very good").
|
Participants will be followed for the duration of their medical visit, an expected average of no more than 2 hours.
|
|
Learning Disabilities of Patients with NF
Time Frame: Participants will be followed for the duration of their medical visit, an expected average of no more than 2 hours.
|
This question asks patients if they have ever been diagnosed with a learning disability.
|
Participants will be followed for the duration of their medical visit, an expected average of no more than 2 hours.
|
|
First Time at NF Clinic
Time Frame: Participants will be followed for the duration of their medical visit, an expected average of no more than 2 hours.
|
This question asks the patient if it's their first time at the MGH NF clinic.
|
Participants will be followed for the duration of their medical visit, an expected average of no more than 2 hours.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Genetic Diseases, Inborn
- Neuromuscular Diseases
- Neurodegenerative Diseases
- Neoplasms, Nerve Tissue
- Peripheral Nervous System Diseases
- Nervous System Neoplasms
- Heredodegenerative Disorders, Nervous System
- Neoplastic Syndromes, Hereditary
- Nerve Sheath Neoplasms
- Neurocutaneous Syndromes
- Peripheral Nervous System Neoplasms
- Neurofibromatoses
- Neurofibromatosis 1
- Neurofibroma
Other Study ID Numbers
- 2014P002755
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neurofibromatosis
-
Pasithea Therapeutics Corp.Novotech (Australia) Pty LimitedRecruitingNeurofibroma, Plexiform | Neurofibroma Plexiform | Neurofibromatosis Type 1 (NF1) | Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs) | NF1 MutationAustralia, United States, South Korea
-
University of Alabama at BirminghamCompletedNeurofibromatosis Type 1 and Growing or Symptomatic, Inoperable PNUnited States
-
Massachusetts General HospitalJohns Hopkins UniversitySuspendedNeurofibromatosis 1 (NF1) | Neurofibromatosis Type IUnited States
-
University of UtahUniversity of British Columbia; Children's Hospital Medical Center, Cincinnati and other collaboratorsTerminatedNeurofibromatosis Type 1 (NF1)United States, Canada
-
Johns Hopkins UniversityNeurofibromatosis Therapeutic Acceleration ProgramActive, not recruitingNeurofibromatosis 1 | Neurofibromatosis Type 1 | Cutaneous Neurofibroma | Neurofibromatosis (Nonmalignant)United States
-
National Cancer Institute (NCI)CompletedPlexiform Neurofibroma | Neurofibromatosis Type IUnited States
-
SpringWorks Therapeutics, Inc., a healthcare company...Active, not recruitingPlexiform Neurofibroma | Neurofibromatosis Type 1 (NF1)United States
-
AstraZenecaCompletedHealthy Participants | Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs)United States
-
NYU Langone HealthNovartis Pharmaceuticals; The Children's Tumor FoundationCompletedNeurofibromatosis Type IIUnited States
-
Novartis PharmaceuticalsTerminatedPlexiform Neurofibroma Associated With Neurofibromatosis Type 1Israel
Clinical Trials on Questionnaires
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)Completed
-
University Hospital, ToulouseNot yet recruiting
-
Direction Centrale du Service de Santé des ArméesCompleted
-
Sun Yat-sen UniversityNot yet recruiting
-
Assistance Publique - Hôpitaux de ParisRecruitingIntensive Care Unit Syndrome | Pediatric Post-intensive Care SyndromeFrance
-
Nova Scotia Health AuthorityNot yet recruitingStroke | Amputation | Spinal Cord Injury | Caregivers | Wheelchair Users | Wheelchair Service ProvidersCanada
-
M.D. Anderson Cancer CenterCompletedAdvanced Cancer | Malignant Neoplasms of Independent (Primary) Multiple SitesUnited States
-
The University of Hong KongCompleted
-
Centre Hospitalier Universitaire DijonCompleted
-
UNC Lineberger Comprehensive Cancer CenterCompletedBreast Cancer | MetastasisUnited States